These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 17405908)
1. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Cerboni C; Zingoni A; Cippitelli M; Piccoli M; Frati L; Santoni A Blood; 2007 Jul; 110(2):606-15. PubMed ID: 17405908 [TBL] [Abstract][Full Text] [Related]
2. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909 [TBL] [Abstract][Full Text] [Related]
3. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. Ward J; Davis Z; DeHart J; Zimmerman E; Bosque A; Brunetta E; Mavilio D; Planelles V; Barker E PLoS Pathog; 2009 Oct; 5(10):e1000613. PubMed ID: 19798433 [TBL] [Abstract][Full Text] [Related]
4. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Wu X; Tao Y; Hou J; Meng X; Shi J Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050 [TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914 [TBL] [Abstract][Full Text] [Related]
6. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells. Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123 [TBL] [Abstract][Full Text] [Related]
7. Distinct Roles for Human Cytomegalovirus Immediate Early Proteins IE1 and IE2 in the Transcriptional Regulation of MICA and PVR/CD155 Expression. Pignoloni B; Fionda C; Dell'Oste V; Luganini A; Cippitelli M; Zingoni A; Landolfo S; Gribaudo G; Santoni A; Cerboni C J Immunol; 2016 Nov; 197(10):4066-4078. PubMed ID: 27733551 [TBL] [Abstract][Full Text] [Related]
8. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia. Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181 [TBL] [Abstract][Full Text] [Related]
9. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8 Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217 [TBL] [Abstract][Full Text] [Related]
11. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260 [TBL] [Abstract][Full Text] [Related]
12. NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients. Dulphy N; Berrou J; Campillo JA; Bagot M; Bensussan A; Toubert A J Invest Dermatol; 2009 Feb; 129(2):359-64. PubMed ID: 18754036 [TBL] [Abstract][Full Text] [Related]
13. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ? Giuliani E; Vassena L; Cerboni C; Doria M Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035 [TBL] [Abstract][Full Text] [Related]
14. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Richard J; Sindhu S; Pham TN; Belzile JP; Cohen EA Blood; 2010 Feb; 115(7):1354-63. PubMed ID: 20008788 [TBL] [Abstract][Full Text] [Related]
15. A nanoscale reorganization of the IL-15 receptor is triggered by NKG2D in a ligand-dependent manner. Bálint Š; Lopes FB; Davis DM Sci Signal; 2018 Apr; 11(525):. PubMed ID: 29636390 [TBL] [Abstract][Full Text] [Related]
16. Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895 [TBL] [Abstract][Full Text] [Related]
17. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection. Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251 [TBL] [Abstract][Full Text] [Related]
18. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Song H; Kim J; Cosman D; Choi I Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603 [TBL] [Abstract][Full Text] [Related]
19. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells. Cerboni C; Ardolino M; Santoni A; Zingoni A Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832 [TBL] [Abstract][Full Text] [Related]
20. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]